Following hypoxic tumor-derived MV uptake by NK cells, the transferred TGF-β1 decreases the NK cell surface expression of the activating receptor NKG2D, thus resulting in NK cell function inhibition. This evidence concerns the gene TGFB1 and neoplasm.